Table 6 Repurposing agent trials between 2016 and 2020
From: Repurposed agents in the Alzheimer’s disease drug development pipeline
2016 | 2017 | 2018 | 2019 | 2020 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
DMTs | Symptomatic agents | DMTs | Symptomatic agents | DMTs | Symptomatic agents | DMTs | Symptomatic agents | DMTs | Symptomatic agents | |
Phase I | 1 | 3 | 1 | 2 | 3 | 2 | 7 | 1 | 8 | 1 |
Phase II | 10 | 7 | 11 | 9 | 15 | 10 | 19 | 7 | 28 | 4 |
Phase III | 4 | 3 | 4 | 4 | 2 | 5 | 3 | 6 | 6 | 6 |
Total | 15 | 13 | 16 | 15 | 20 | 17 | 29 | 14 | 42 | 11 |